[ad_1]
Eli Lilly said bamlanivimab reduced the risk of contracting symptomatic Covid-19 in a first-of-its-kind trial involving residents and nursing home staff, paving the way for a new option for protection against the virus.
But the magnitude of the impact this could have and the role it will play as vaccines are rolled out to the exact population they are targeting are still unclear.
Among the 965 study participants – all of whom tested negative for the coronavirus initially – the number of symptomatic cases reported in the bamlanivimab arm was 57% lower than in the placebo arm (odds ratio 0.43, p = 0.00021). In addition to this primary endpoint, all secondary endpoints reached statistical significance.
Keep Reading Endpoints With A Free Membership
Unlock this story instantly and join over 98,500 biopharmacy pros by reading Endpoints every day – and it’s free.
[ad_2]
Source link